Author

E. Postnikova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1

Frequent Co-Authors

M. Holbrook· 2 shared A. B. Ward· 1 shared A. Pegu· 1 shared C. A. Talana· 1 shared C. Chiu· 1 shared C. Dacon· 1 shared C. Finch· 1 shared C. Goodin· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

M. Holbrook

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants

H. Cho, K. K. Gonzales-Wartz, D. Huang, M. Yuan, M. Peterson, J. Liang, N. Beutler, J. L. Torres, Y. Cong, E. Postnikova, S. Bangaru, C. A. Talana, W. Shi, E. S. Yang, Y. Zhang, , J. Tan

This study identifies ultrapotent bispecific antibodies that neutralize emerging SARS-CoV-2 variants by targeting multiple spike protein regions, showing efficacy in vitro and in a hamster model.

bioRxiv · Apr 1, 2021 · PreprintImmunology

Repurposing Pyramax for the Treatment of Ebola Virus Disease: Additivity of the Lysosomotropic Pyronaridine and Non-Lysosomotropic Artesunate

T. R. Lane, J. Dyall, L. Mercer, C. Goodin, D. H. Foil, H. Zhou, E. Postnikova, J. Y. Liang, M. Holbrook, P. Madrid, S. Ekins

The paper evaluates the antiviral efficacy of Pyramax(R), a malaria treatment, against Ebola virus and finds its components act additively to inhibit infection.

bioRxiv · Apr 25, 2020 · PreprintPharmacology & Toxicology

Human, Nonhuman Primate, and Bat Cells Are Broadly Susceptible to Tibrovirus Particle Cell Entry

Y. Cai, S. Yu, R. Jangra, E. Postnikova, J. Wada, R. Tesh, S. Whelan, M. Lauck, M. Wiley, C. Finch, S. Radoshitzky, D. O'Connor, G. Palacios, K. Chandran, C. Chiu, J. Kuhn

The paper shows that tibrovirus glycoproteins can enter human, bat, and nonhuman primate cells, but replication resistance varies among cell types.

bioRxiv · Dec 27, 2018Microbiology